Mésothéliomes malins et mutations constitutionnelles du gène BAP1

Nevière, Zoé; Berthet, Pascaline; Polycarpe, Florence; Dubos-Arvis, Catherine; Dô, Pascal; Gervais, Radj

doi:10.1016/j.rmr.2017.11.014

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, germline mutations in different genes mainly involved in DNA damage repair confer moderate-to-high genetic risk of MPM development (25). The BAP1-tumor predisposition syndrome is the most studied genetic condition associated with MPM development and is caused by mutations in the BRCA1-associated protein 1 (BAP1) gene (14,(26)(27)(28)(29)(30)(31)(32). This new evidence should be taken into account together with environmental/occupational exposures, as it may lead to a different risk stratification.…”

Section: Introductionmentioning

confidence: 99%

Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation

et al. 2020

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers in easily accessible samples (such as blood) for early diagnosis of MPM. In the last 10 years, epigenetic markers, such as DNA methylation and microRNAs (miRNAs), have gained popularity as possible early diagnostic and prognostic biomarkers in cancer research. The aim of this review is to provide a critical analysis of the current evidences on circulating epigenetic biomarkers for MPM and on their translational potential to the clinical practice for early diagnosis and for prognosis.

show abstract